These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32405278)

  • 1. Pharmacotherapy for hospitalized patients with COVID-19: Waiting or doing?
    Amariles P; Hincapie-García J; Julio Montoya C
    Res Social Adm Pharm; 2021 Jan; 17(1):2049. PubMed ID: 32405278
    [No Abstract]   [Full Text] [Related]  

  • 2. Just the facts: updates in COVID-19 therapeutics.
    Long B; Liang SY; Rosenberg H; Hicks C; Gottlieb M
    CJEM; 2021 May; 23(3):283-285. PubMed ID: 33555601
    [No Abstract]   [Full Text] [Related]  

  • 3. Audio Interview: Choosing an Antiviral to Treat Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2022 Aug; 387(8):e22. PubMed ID: 36001719
    [No Abstract]   [Full Text] [Related]  

  • 4. COVID antibody treatments show promise for preventing severe disease.
    Ledford H
    Nature; 2021 Mar; 591(7851):513-514. PubMed ID: 33712752
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity.
    Lin KJ; Schneeweiss S; Tesfaye H; D'Andrea E; Liu J; Lii J; Murphy SN; Gagne JJ
    Drugs; 2020 Dec; 80(18):1961-1972. PubMed ID: 33151482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.
    Singh A
    Ann Intern Med; 2021 Jan; 174(1):JC3. PubMed ID: 33395331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future of antivirals in COVID-19: The case of favipiravir.
    Kow CS; Ramachandram DS; Hasan SS
    Int Immunopharmacol; 2022 Feb; 103():108455. PubMed ID: 34959188
    [No Abstract]   [Full Text] [Related]  

  • 8. An Example of Employing the Principles of Bioethics to Medical Decision Making in the COVID-19 Era.
    Ruhl DS; Hohman MH
    Laryngoscope; 2020 Nov; 130(11):2688-2689. PubMed ID: 32535910
    [No Abstract]   [Full Text] [Related]  

  • 9. COVID-19 clinical trials: Ethical and scientific consequences of the RECOVERY trial results.
    Dal-Ré R; Porcher R; Gluud C
    Basic Clin Pharmacol Toxicol; 2020 Dec; 127(6):445-447. PubMed ID: 32931136
    [No Abstract]   [Full Text] [Related]  

  • 10. Timing of remdesivir for COVID-19.
    Med Lett Drugs Ther; 2020 Oct; 62(1609):161. PubMed ID: 33429407
    [No Abstract]   [Full Text] [Related]  

  • 11. Molnupiravir: A new candidate for COVID-19 treatment.
    Pourkarim F; Pourtaghi-Anvarian S; Rezaee H
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00909. PubMed ID: 34968008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication Use Patterns in Hospitalized Patients With COVID-19 in California During the Pandemic.
    Watanabe JH; Kwon J; Nan B; Abeles SR; Jia S; Mehta SR
    JAMA Netw Open; 2021 May; 4(5):e2110775. PubMed ID: 34019090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Hosseini FS; Malektojari A; Ghazizadeh S; Hassaniazad M; Davoodian P; Dadvand H; Nikpoor AR; Nikoofal-Sahlabadi S; Kahoori S; Sepandi M; Hassanipour S; Fathalipour M
    Trials; 2021 Jan; 22(1):4. PubMed ID: 33397429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicine's longest year.
    Servick K; Couzin-Frankel J; Matacic C
    Science; 2021 Mar; 371(6535):1195-1199. PubMed ID: 33737471
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials.
    Kow CS; Hasan SS
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1089-1094. PubMed ID: 33532896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remdesivir (Veklury) for the Treatment of COVID-19 in Hospitalized Patients.
    Odeti S; Yellepeddi VK
    Am Fam Physician; 2021 Sep; 104(3):311-312. PubMed ID: 34523893
    [No Abstract]   [Full Text] [Related]  

  • 17. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics.
    Kalil AC
    JAMA; 2020 May; 323(19):1897-1898. PubMed ID: 32208486
    [No Abstract]   [Full Text] [Related]  

  • 18. Introduction to the Special Section: COVID-19 - insights on pharmacology and pharmacotherapy.
    Sanak M
    Pharmacol Rep; 2020 Dec; 72(6):1445. PubMed ID: 33206322
    [No Abstract]   [Full Text] [Related]  

  • 19. Home pharmacological therapy in early COVID-19 to prevent hospitalization and reduce mortality: Time for a suitable proposal.
    Pandolfi S; Chirumbolo S; Ricevuti G; Valdenassi L; Bjørklund G; Lysiuk R; Doşa MD; Lenchyk L; Fazio S
    Basic Clin Pharmacol Toxicol; 2022 Feb; 130(2):225-239. PubMed ID: 34811895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System.
    Yeramaneni S; Doshi P; Sands K; Cooper M; Kurbegov D; Fromell G
    Gastroenterology; 2021 Feb; 160(3):919-921.e3. PubMed ID: 33058865
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.